A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice

Multiple FDA-approved SARS-CoV-2 vaccines provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- and vaccination-induced immunity continue to emerge. Intranasal (IN) vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jangra, Sonia, Landers, Jeffrey J., Laghlali, Gabriel, Rathnasinghe, Raveen, O’Konek, Jessica. J., Janczak, Katarzyna W., García-Sastre, Adolfo, Baker, James R., Schotsaert, Michael, Wong, Pamela T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882683/
https://www.ncbi.nlm.nih.gov/pubmed/36711479
http://dx.doi.org/10.21203/rs.3.rs-2457013/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882683/
https://www.ncbi.nlm.nih.gov/pubmed/36711479
http://dx.doi.org/10.21203/rs.3.rs-2457013/v1

Ejemplares similares